Overcoming the obstacles in the pharma/biotech industry: 2009 Update

Drug News and Perspectives

Volumn 23, Issue 1, 2010, Pages 48-63

  Graul, Ann I ^a   Revel, Laura ^a   Tell, Montserrat ^a   Rosa, Esmeralda ^a   Cruces, Elisabet ^a  

^a Editorial Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE; AXITINIB; BUDESONIDE; CANDESARTAN HEXETIL; EFALIZUMAB; ETHINYLESTRADIOL; LANSOPRAZOLE; LEVONORGESTREL; MALATHION; MELANOMA VACCINE; MELPHALAN; MEPOLIZUMAB; MIVACURIUM; NATEGLINIDE; NORETHISTERONE ACETATE; OXALIPLATIN; OXCARBAZEPINE; PERINDOPRIL; PIPERACILLIN; RAMELTEON; ROSIGLITAZONE; SAREDUTANT; SARPOGRELATE; SUMATRIPTAN SUCCINATE; TACROLIMUS; TAZOBACTAM; UNINDEXED DRUG; VANDETANIB; VITESPEN; VOLOCIXIMAB;

BIOTECHNOLOGY; DRUG APPROVAL; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; REVIEW;

CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 77950624325     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.1.1437302     Document Type: Review

References (33)

1. Engelberg, A.B. et al. Balancing innovation, access, and profits - Market exclusivity for biologics. New Engl J Med 2009,361(20): 1917-1919
2. Generic Pharmaceutical Association annual report 2009. Available at http://www.gphaonline.org/sites/default/files/gpha-low-res.pdf. Accessed December 2, 2009.
3. European Generic Medicines Association. Europe's strongly competitive generic medicines industry warns of increasing burdens and hurdles. European Generic Medicines Association Press Release, January 28, 2009.
4. Capell, K. How big pharma profits from swine flu. BusinessWeek 2009, November 24. Available at http://www.businessweek.com/globalbiz/content/nov2009/ gb20091124-846373.htm. Accessed November 30, 2009.
5. Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2009 (PhRMA, April 2009). Available at http://www.phrma.org/ files/PhRMA%202009%20Profile%20FINAL.pdf. Accessed November 24, 2009.
6. Tufts Center for the Study of Drug Development. Marketing exclusivity for first-in-class drugs has shortened to 2.5 years. Tufts Center for the Study of Drug Development press release, September 9, 2009. Available at http://csdd.tufts.edu/NewsEvents/NewsArticle.asp?newsid=153. Accessed November 26, 2009.
7. Gottlieb, S. Biosimilars: Policy, clinical, and regulatory considerations. Am J Health-Syst Pharm 2008, 65(Suppl. 6): S2-8.
8. Schellekens, H. Biosimilar therapeutics -What do we need to consider? NDT Plus 2009, 2(Suppl. 1): 127-136
9. Hodgson, J. WHO guidelines presage US biosimilars legislation? Nat Biotech 2009, 27(11): 963-965
10. Dudzinski, D.M., Kesselheim, A.S. Scientific and legal viability of follow-on protein drugs. New Engl J Med 2008, 358(8): 843-849
11. Pharmaceutical Research and Manufacturers Association. PhRMA statement supporting fair Incentives for biologies innovation. Pharma-ceutical Research and Manufacturers Association Press Release, October 19, 2009.
12. WHO Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Available at http://www.who.int/biologicals/publications/trs/areas/biological.therapeutics/ BS2110Dft-guidelines-Final-HK-IK-29July-09.pdf. Accessed December 3, 2009.
13. Mellstedt, H., Niederwieser, D., Ludwig, H. The challenge of biosimilars. Ann Oncol 2008, 19(3): 411-419
14. Tufts Center for the Study of Drug Development. Outlook 2009. Available at http://csdd.tufts.edu/lnfoServices/OutlookPDFs/Outlook2009.pdf. Accessed November 26,2009.
15. Tufts Center for the Study of Drug Development. Large pharmaceutical firms are getting more drugs into development while terminating unpromising candidates. Tufts Center for the Study of Drug Development news release, July 22, 2009. Available at http://csdd.tufts.edu/NewsEvents/NewsArticle.asp?newsid= 152. Accessed November 26, 2009.
16. London: Center for Medicines Research International. CMR International 2008 Pharmaceutical R&D Factbook. May 2008.
17. Weiss, D., Naik, P., Weiss, R. The 'big pharma' dilemma: Develop new drugs or promote existing ones? Nat Rev Drug Discov 2009, 8(7): 533-534
18. Jørgensen, J.T. Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development. Expert Rev Mol Diagn 2008, 8(6): 689-695
19. Leeder, J.S., Spielberg, S.P. Personalized medicine: Reality and reality checks. Ann Pharmacother 2009, 43(5): 963-966
20. Frueh, F.W. Back to the future: Why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics 2009, 10(7): 1077-1081
21. Lee, S.S., Mudaliar, A. Medicine. Racing forward: The genomics and personalized medicine act. Science 2009, 323(5912): 342-344
22. Graul, A.I., Prous, J.R. The year's new drugs. Drug News Perspect 2006, 19(1): 33-53.
23. Washington DC: Pharmaceutical Research and Manufacturers Association of America. Medicines in development for major diseases affecting African Americans. 2007.
24. Washington DC: Pharmaceutical Research and Manufacturers Association of America. Medicines in development for major diseases affecting Hispanic Americans. 2006.
25. Glickman, S.W., McHutchison, J.G., Peterson, E.D., Cairns, C.B., Harrington, R.A., Califf, R.M., Schulman, K.A. Ethical and scientific implications of the globalization of clinical research. New Engl J Med 2009, 360(8): 816-823
26. Pandey, A., Aggarwal, A., Seth, S., Maulik, M., Bano, R., Juneja, A. Clinical trials registry -India: Redefining the conduct of clinical trials. lnd J Cancer 2008, 45(3): 79-82.
27. Chatterjee, P. Clinical trials in India: Ethical concerns. Bull WHO 2008, 86(8): 581-582
28. Cuatrecasas, P. Pedro Cuatrecasas. Nat Rev Drug Discov 2009, 8(6): 446.
29. Munos, B. Can open-source R&D reinvigorate drug research? Nat Rev Drug Discov 2006, 5(9): 723-729
30. Bloomberg. Pfizer may cut $3 billion in research deal with Wyeth (update 3). Bloomberg News Release, October 19, 2009. Available at http://www.bloomberg.com/apps/news?pid=20601103&sid=a8U9oCkKn5dU. Accessed December 4, 2009.
31. Singer, N. Merck to buy Schering-Plough for $41.1 billion. New York Times, March 9, 2009. Available at http://www.nytimes.com/2009/03/10/ business/10drug.html. Accessed December 4, 2009.
32. Pollack, A. Roche agrees to buy Genentech for $46.8 billion. New York Times, March 12, 2009. Available at http://www.nytimes.com/2009/03/13/ business/worldbusiness/13drugs.html. Accessed December 4, 2009.
33. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat rev Drug Discov 2009, 8(12): 959-968